Wockhardt informs about press release

31 Jan 2025 Evaluate
Pursuant to Regulation 30 of Listing Regulations, Wockhardt has informed that it enclosed Press Release titled ‘Wockhardt’s Zaynich® (Zidebactam/Cefepime, WCK 5222) achieves highest-ever efficacy meeting superiority in a global, pivotal, registration-enabling Phase III study in complicated urinary tract infection (cUTI) achieving 96.8% clinical cure rate’. A copy of the same will also be uploaded on the Company’s website www.wockhardt.com.

The above information is a part of company’s filings submitted to BSE.

Wockhardt Share Price

1158.65 -9.30 (-0.80%)
28-Feb-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1593.90
Dr. Reddys Lab 1117.65
Cipla 1410.95
Lupin 1906.20
Zydus Lifesciences 876.20
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...